Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC (PC-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05993858

Recruitment Status : Not yet recruiting

First Posted : August 15, 2023

Last Update Posted : August 15, 2023

See Contacts and Locations

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Wuhan Union Hospital, China

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Not yet recruiting
Estimated Primary Completion Date :	December 20, 2025
Estimated Study Completion Date :	December 20, 2026

To Top